Sangamo Therapeutics, Inc. SGMO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO

SGMO 0.426

-7.6%

Dec 1 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who started this subject	3/6/2002 3:33:07 AM
From: nigel bates	of 368

Sangamo BioSciences Granted U.K. Patent Covering Design and Synthesis of Zinc Finger DNA-Binding Proteins RICHMOND, Calif., March 5 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - news) announced today that the company has been granted a patent in the United Kingdom entitled ``Selection of Sites for Targeting by Zinc Finger Proteins and Methods of Designing Zinc Finger Proteins to Bind to Pre-selected Sites.'' The patent includes claims covering methods for designing and synthesizing zinc finger DNA-binding proteins (ZFPs) that can specifically bind to DNA target sequences within any gene. ``The granting of this patent adds to our already significant intellectual property portfolio in the area of ZFP design and reinforces Sangamo's position as the worldwide leader in the design, engineering and use of ZFPs,'' said Edward Lanphier, Sangamo's president and chief executive officer. ``Using these methods, ZFPs that recognize sequences in virtually any gene can be readily synthesized by drawing on the existing library of individual finger designs that we have already generated and tested.'' Zinc finger DNA-binding proteins are the dominant class of naturally occurring transcription factors in organisms from yeast to humans. Transcription factors bind to DNA to regulate gene expression. Transcription factors made from ZFPs (ZFP TFs) allow precise targeting to a particular gene or genes of interest. Since the over-expression or under-expression of individual genes is the basis for many diseases, the ability to regulate genes with engineered ZFP TFs has significant potential therapeutic benefit. The inventions covered by U.K. patent GB 2,360,285 were made by Sangamo scientists who have developed databases of ZFPs, along with their binding specificities, to provide individual zinc finger modules which can be assembled in any combination to generate new ZFPs with novel DNA binding specificities. The databases include naturally occurring zinc finger proteins, as well as ZFPs obtained by design or selection. Counterpart patent applications with similar claims are pending internationally...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next